Kymera Therapeutics, a clinical-stage biopharmaceutical company, is initiating a public offering of $500.0 million of its common stock.
The company intends to use the proceeds to advance its pipeline of preclinical and clinical degrader programs for immunological diseases.
Joint book-running managers for the offering include Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities, and Wells Fargo Securities.
Proposed Offering Details
A $500.0 million public offering of common stock with an option for an additional $75.0 million, underwritten by Kymera Therapeutics.
Use of Proceeds
Funds will support the development of new oral small molecule degrader medicines and general corporate purposes.
Book-Running Managers
Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities, and Wells Fargo Securities are overseeing the offering.
- Kymera Therapeutics aims to address large patient populations with significant medical needs and commercial opportunities through its new medicines.
- The company's focus on targeted protein degradation may revolutionize how critical health problems are treated.
Kymera Therapeutics' proposed public offering signifies a strategic move to advance its innovative pipeline and provide highly effective therapies for patients in need.